Chronic kidney disease, hyperparathyroidism and vitamin D

Authors

  • María Jimena Soutelo Churruca Visca Hospital; Argentine Diabetes Society, Autonomous City of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/diab.v51i3.109

Keywords:

secondary hyperparathyroidism, bone-mineral alterations associated with chronic kidney disease, cardiovascular mortality, PTH, vitamin d

Abstract

Secondary hyperparathyroidism is a common complication of the chronic kidney disease (CKD). The most frequent consequence of HTP2 is bone disease, but it is worth mentioning that elevated levels of PTH correlated directly with extra bone diseases. In diabetic patients and kidney disease, a follow-up and control should be performed to avoid complications of the phosphocalcic metabolism and reduce the risk of anemia and cardiovascular disease. The ionic mo- vements can be observed at early stages of the CKD. Calcium, phosphorus, PTH, FAL and vitamin D measurements are recommended with a GF <60ml/min and supplement with vitamin D if values are <30 ng/dl.

Author Biography

María Jimena Soutelo, Churruca Visca Hospital; Argentine Diabetes Society, Autonomous City of Buenos Aires, Argentina

Medical specialist in Endocrinology, Hospital Churruca Visca, Endocrinology Service; Member of the Nephropathy Committee of the Argentine Diabetes Society

References

Komaba H, Kakuta T, Fukagawa M. Management of secondary hyperparathyroidism: how and why? Clin Exp Nephrol 2017; 21 (Supl 1): S37-S45.

KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; 113:S1-S130.

Bellorin-Font E, Ambrosoni P, Carlini RG, et al. Comité de Metabolismo Mineral y Óseo, Sociedad Latinoamericana de Nefrología e Hipertensión (SLANH). Clinical Practice Guidelines for the Prevention, Diagnosis, Evaluation and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease (CKD-MBD) in Adults. Nefrologia 2013; 33 (Suppl.1):1-28.

Kuro-o. M. The FGF23 and Klotho system beyond mineral metabolism. Clin Exp Nephrol 2017; 21 (Suppl 1): S64-S69.

Kazama JJ. Chronic kidney disease and fragility fracture. Clin Exp Nephrol 2017; 21 (Supl 1): S46-S52.

Kramer H, Berns JS, Choi MJ, Martin K, Rocco MV. 25-Hydroxyvitamin D testing and supplementation in CKD: An NKF-KDOQI controversies report. Am J Kidney Dis 2014; 64(4):499-509.

Alderson HV, Ritchie JP, Green D, et al. Potential for biomarkers of chronic kidney disease-mineral bone disorder to improve patient care. Nephron Clin Pract. 2013; 124:141-150.

Jackuliak P, Payer J. Osteoporosis, fractures, and diabetes. International Journal of Endocrinology Vol 2014, Article ID 820615, 10. http://dx.doi. org/10.1155/2014/820615.

Arboleya L.Trastorno mineral y óseo asociado a la enfer- medad renal crónica. Reumatol Clin 2011; 7(S2):S18-S21.

KDIGO 2016 Clinical Practice Guideline Update on Diagnosis, Evaluation, Prevention and Treatment of CKD-MBD.

Published

2023-01-10

How to Cite

Soutelo, M. J. (2023). Chronic kidney disease, hyperparathyroidism and vitamin D. Journal of the Argentine Society of Diabetes, 51(3), 103–107. https://doi.org/10.47196/diab.v51i3.109

Issue

Section

Conferences and congresses

Most read articles by the same author(s)

1 2 > >>